NovoCure Reports Third Quarter 2016 Financial Results And Provides Company Update

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR), a commercial stage oncology company pioneering a proprietary therapy for solid tumors, today reported financial results for the quarter ended September 30, 2016, highlighting year-over-year and sequential growth in prescriptions, active patients and revenues.

Back to news